Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines

J. Schuster, Stephen; L. Bartlett, Nancy; Assouline, Sarit; Yoon, Sung‐Soo; Bosch, Francesc; H. Sehn, Laurie; Y. Cheah, Chan; Shadman, Mazyar; P. Gregory, Gareth; Ku, Matthew; C. Wei, Michael; Yin, Shen; Kwan, Antonia; Yousefi, Kasra; Hernandez, Genevive; Li, Chi‐Chung; O’Hear, Carol; E. Budde, Lihua

doi:10.1182/blood-2019-123742

Public

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines

Published in Blood • Nov 13, 2019

Authors:

Stephen J. Schuster

Nancy L. Bartlett

Sarit Assouline

Abstract

Introduction: Improved treatments are needed for relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) pts. Options are particularly limited for pts with B-cell NHLs who are R/R to CAR-T therapies or for whom a delay in effective therapy precludes this approach. Mosunetuzumab (M; RG7828) is a full...

Subject

Medicine

Tolerability

Internal medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!